After more than two decades managing Crohn’s disease, I’ve tried my share of supplements. Probiotics came up early — friends recommended them, I saw them in health food stores, and the logic seemed sound: if IBD involves gut bacteria, why not add “good” bacteria back?

The honest answer I’ve landed on: most probiotics probably aren’t worth the money for IBD, but a few specific strains have enough evidence that I’d consider them as part of a broader treatment approach. Not as primary therapy, but as something that might help at the margins.

What the Research Actually Shows

I’ve read through dozens of probiotic studies over the years, and the picture is mixed. Most of the positive findings come from small studies with short follow-up periods. The few larger, longer trials often show modest benefits at best.

But there are exceptions. The strain with the strongest evidence in IBD is E. coli Nissle 1917, sold as Mutaflor in Europe. A 2004 study in Gut followed 327 ulcerative colitis patients in remission for one year. Those taking E. coli Nissle had similar remission rates to those on mesalamine — about 68% stayed in remission in both groups. That’s not groundbreaking, but it suggests this particular strain might help maintain remission in UC.

For Crohn’s specifically, the evidence is thinner. A 2002 Cochrane review found no clear benefit from probiotics in Crohn’s disease. More recent studies haven’t dramatically changed that picture, though some small trials suggest certain multi-strain formulations might reduce inflammatory markers.

The probiotic with the most compelling data for pouchitis — relevant for IBD patients who’ve had colectomy — is VSL#3 (now called Visbiome after a legal dispute). Multiple studies show it can help prevent pouchitis recurrence, with one trial showing a 90% success rate compared to 60% with placebo over eight months.

What This Means for Me Right Now

Having been on Remicade for years and recently transitioned to Rinvoq, I don’t see probiotics as a substitute for proven IBD therapy. They’re not going to replace my biologic or change my monitoring schedule.

But I do think there’s enough evidence for specific strains that I’d consider adding them, particularly during times when I’m concerned about maintaining remission or if I’m dealing with antibiotic-associated symptoms.

If I were going to try probiotics, I’d focus on the strains with actual IBD data: E. coli Nissle for general IBD management, or Visbiome if I had a pouch. I wouldn’t bother with the generic multi-strain products you find at most pharmacies — there’s no good reason to think they work better than the studied formulations, and they often contain different strains entirely.

The Limitations I Keep in Mind

Most probiotic research in IBD suffers from the same problems: small sample sizes, short follow-up periods, and heterogeneous patient populations. Many studies lump different IBD subtypes together, which makes it hard to know if a finding applies to someone with my particular disease pattern.

There’s also the basic challenge that we don’t really understand how probiotics work in IBD, assuming they work at all. The mechanism could be direct bacterial competition, immune modulation, or something else entirely. Without understanding the mechanism, it’s hard to predict who might benefit.

And then there’s the regulatory issue: probiotics are sold as supplements, not drugs, which means quality control varies widely. The strain and dose you’re actually getting might not match what was studied.

My Practical Approach

After years of reading this literature, my approach is cautiously pragmatic. I don’t take probiotics routinely, but I keep Visbiome in mind as something I might try during specific situations — after a course of antibiotics, during a period of increased stress, or if I’m experiencing symptoms that might benefit from additional gut support.

I wouldn’t expect dramatic results. The best-case scenario from the research is modest improvement in some patients, not remission induction or major symptom relief. That’s fine — not every intervention needs to be transformative to be worthwhile.

What I won’t do is spend money on expensive probiotic blends without IBD-specific evidence, or view them as a primary treatment strategy. I’ve learned over two decades that managing Crohn’s effectively means focusing resources on interventions with the strongest evidence base, not chasing every supplement that sounds plausible.

The field is still evolving. Researchers are working on more targeted approaches — specific strains for specific patient populations, personalized selection based on microbiome testing, engineered bacteria designed for particular therapeutic effects. Those developments might change the calculation in the coming years.

For now, I file probiotics under “potentially helpful, probably not harmful, definitely not essential.” That’s not the most exciting conclusion, but after 20+ years of managing a chronic disease, I’ve learned that boring, evidence-based decisions usually serve me better than exciting ones.